Immunai vs FORE Biotherapeutics

Immunai vs FORE Biotherapeutics, compared side by side on 22 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Immunai is on 69/100 and FORE Biotherapeutics on 56/100.

Immunai logo
ImmunaiMapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.
Try Immunai
FORE Biotherapeutics logo
FORE BiotherapeuticsPrecision oncology company developing cancer therapies guided by proprietary functional genomics.
Try FORE Biotherapeutics

Where each one leads

Immunai

  • our overall score: 69/100 against 56/100
  • domain rating: 46/100 against 33/100
  • headcount: 179 against 56
  • headcount growth: +13.0% against +8.2%
  • funding raised: $295M against $232M
  • LinkedIn following: 26,832 against 4,584

FORE Biotherapeutics

  • agent readiness: 37/100 against 32/100

At a glance

MeasureImmunaiFORE Biotherapeutics
What it isMapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.Precision oncology company developing cancer therapies guided by proprietary functional genomics.
CategoryHealthcare, Immunology, Data, AnalyticsHealthcare, Drug Development, Genomics, Next Generation Sequencing
Sells toBusiness modelB2BB2B
OfferingSoftwareSoftware
Founded20192011
HeadquartersNew York, United StatesPhiladelphia, United States
StatusActiveActive

Size, funding and growth

MeasureImmunaiFORE Biotherapeutics
Employees17956
Headcount growthLast 12 months+13.0%+8.2%
Total funding$295M$232M
Latest roundSeries BSeries D-2 Extension
Valuation$1.0B$75.0M
LinkedIn followers26,8324,584

StartupHub scores

Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.

MeasureImmunaiFORE Biotherapeutics
StartupHub scoreOur 0-100 rating69/10056/100
Traction60/10058/100
Team70/10070/100
Search visibility39/10038/100
Quality78/10055/100
Agent readinessHow well an AI agent can read and act on the siteF (32/100)F (37/100)
Domain ratingLink authority, 0-10046/10033/100

Technology

Detected on each public site, so it reflects the marketing stack as well as the product.

MeasureImmunaiFORE Biotherapeutics
CMSWordPressWordPress
FrameworksJquery, BootstrapJquery
AnalyticsGoogle Tag ManagerNot detected

Immunai vs FORE Biotherapeutics: common questions

Which is better, Immunai or FORE Biotherapeutics?

On our 0-100 score Immunai rates higher (69/100 against 56/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 22 data points above: read the rows that match what you are buying for.

How do Immunai and FORE Biotherapeutics compare on the numbers?

Immunai leads on our overall score (69/100 against 56/100), domain rating (46/100 against 33/100), headcount (179 against 56), headcount growth (+13.0% against +8.2%), funding raised ($295M against $232M), LinkedIn following (26,832 against 4,584). FORE Biotherapeutics leads on agent readiness (37/100 against 32/100).

Read the full Immunai review and pricing or the FORE Biotherapeutics review and pricing. You can also browse other Immunai alternatives we track.